Ahead of a CPHI North America panel discussion, “Redesigning the Supply Chain – The Road to Increased Resilience,” Bikash Chatterjee, CEO of Pharmatech Associates, a USP company, forewarns that CDMO supply chains are potentially the biggest single risk to product resilience, yet remain an area often overlooked by drug sponsors in partnering criteria. With many of the largest CDMOs now running at capacity, drug sponsors will need to focus on mitigating risk and building resiliency when using s...